Esteve joins innovative HIV/AIDS partnership
This article was originally published in Scrip
The Spanish chemical and pharmaceutical group Esteve is to collaborate with the IrsiCaixa AIDS Research Institute on the HIVACAT AIDS research project to develop an HIV vaccine.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.